PLoS Biology (Feb 2023)

Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs.

  • Lipin Loo,
  • Matthew A Waller,
  • Cesar L Moreno,
  • Alexander J Cole,
  • Alberto Ospina Stella,
  • Oltin-Tiberiu Pop,
  • Ann-Kristin Jochum,
  • Omar Hasan Ali,
  • Christopher E Denes,
  • Zina Hamoudi,
  • Felicity Chung,
  • Anupriya Aggarwal,
  • Jason K K Low,
  • Karishma Patel,
  • Rezwan Siddiquee,
  • Taeyoung Kang,
  • Suresh Mathivanan,
  • Joel P Mackay,
  • Wolfram Jochum,
  • Lukas Flatz,
  • Daniel Hesselson,
  • Stuart Turville,
  • G Gregory Neely

DOI
https://doi.org/10.1371/journal.pbio.3001967
Journal volume & issue
Vol. 21, no. 2
p. e3001967

Abstract

Read online

Although ACE2 is the primary receptor for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, a systematic assessment of host factors that regulate binding to SARS-CoV-2 spike protein has not been described. Here, we use whole-genome CRISPR activation to identify host factors controlling cellular interactions with SARS-CoV-2. Our top hit was a TLR-related cell surface receptor called leucine-rich repeat-containing protein 15 (LRRC15). LRRC15 expression was sufficient to promote SARS-CoV-2 spike binding where they form a cell surface complex. LRRC15 mRNA is expressed in human collagen-producing lung myofibroblasts and LRRC15 protein is induced in severe Coronavirus Disease 2019 (COVID-19) infection where it can be found lining the airways. Mechanistically, LRRC15 does not itself support SARS-CoV-2 infection, but fibroblasts expressing LRRC15 can suppress both pseudotyped and authentic SARS-CoV-2 infection in trans. Moreover, LRRC15 expression in fibroblasts suppresses collagen production and promotes expression of IFIT, OAS, and MX-family antiviral factors. Overall, LRRC15 is a novel SARS-CoV-2 spike-binding receptor that can help control viral load and regulate antiviral and antifibrotic transcriptional programs in the context of COVID-19 infection.